ARTICLE | Clinical News

Pulmaquin liposomal ciprofloxacin: Phase III start

March 26, 2012 7:00 AM UTC

This year, Aradigm will begin a double-blind, placebo-controlled, international Phase III trial to evaluate 210 mg inhaled Pulmaquin daily for 28 days and then 28 days off for 6 cycles in about 250 pa...